Panduranga Prashanth, El-Deeb Mohammed, Jha Chitra
Departments of Cardiology, Royal Hospital, Muscat, Oman.
Obstetrics & Gynaecology, Royal Hospital, Muscat, Oman.
Sultan Qaboos Univ Med J. 2014 Nov;14(4):e448-54. Epub 2014 Oct 14.
Choosing the best anticoagulant therapy for a pregnant patient with a mechanical prosthetic valve is controversial and the published international guidelines contain no clear-cut consensus on the best approach. This is due to the fact that there is presently no anticoagulant which can reliably decrease thromboembolic events while avoiding damage to the fetus. Current treatments include either continuing oral warfarin or substituting warfarin for subcutaneous unfractionated heparin or low-molecular-weight heparin (LMWH) in the first trimester (6-12 weeks) or at any point throughout the pregnancy. However, LMWH, while widely-prescribed, requires close monitoring of the blood anti-factor Xa levels. Unfortunately, facilities for such monitoring are not universally available, such as within hospitals in developing countries. This review evaluates the leading international guidelines concerning anticoagulant therapy in pregnant patients with mechanical prosthetic valves as well as proposing a simplified guideline which may be more relevant to hospitals in this region.
为患有机械人工瓣膜的孕妇选择最佳抗凝治疗方案存在争议,已发布的国际指南对于最佳治疗方法并未达成明确共识。这是因为目前尚无一种抗凝剂能够在避免对胎儿造成损害的同时可靠地降低血栓栓塞事件的发生。当前的治疗方法包括在孕早期(6 - 12周)或整个孕期的任何时间继续使用口服华法林,或者将华法林替换为皮下注射普通肝素或低分子量肝素(LMWH)。然而,尽管LMWH被广泛应用,但需要密切监测血液中的抗Xa因子水平。不幸的是,并非所有地方都具备进行这种监测的条件,比如发展中国家的医院。本综述评估了关于患有机械人工瓣膜的孕妇抗凝治疗的主要国际指南,并提出了一个可能更适用于该地区医院的简化指南。